Indication: Multiple Myeloma
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Sponsor: Regeneron Pharmaceuticals, Inc.
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
